

Virulence of atypical *Toxoplasma gondii* strains isolated in French Guiana in a murine model

Stéphane Simon^{1,2,*}, Benoit de Thoisy³, Aurélien Mercier^{4,5}, Mathieu Nacher^{1,6}, and Magalie Demar^{1,2}

¹ Equipe EA3593 – Ecosystèmes Amazoniens et Pathologie Tropicale, Université de la Guyane, 97300 Cayenne, French Guiana

² Laboratoire de Parasitologie – Mycologie, Cayenne General Hospital, 97300 Cayenne, French Guiana

³ Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, 97300 Cayenne, French Guiana

⁴ INSERM UMR_S 1094, Neuroépidémiologie Tropicale, Laboratoire de Parasitologie-Mycologie, Faculté de Médecine, Université de Limoges, Limoges 87025, France

⁵ Centre National de Référence Toxoplasmose/Toxoplasma Biological Ressource Center, CHU Limoges, 87042 Limoges, France

⁶ Centre d'Investigation Clinique Epidémiologie Clinique Antilles Guyane CIC CIE 1424, Cayenne General Hospital, 97300 Cayenne, French Guiana

Received 25 January 2019, Accepted 25 July 2019, Published online 24 September 2019

Abstract – Background. *Toxoplasma gondii* is an obligate intracellular protozoan parasite of warm-blooded vertebrates. Most infections in immunocompetent patients are asymptomatic. However, since 2000s, strains with particular genetic profiles that differ from the known clonal type (type I, II, III), have been described. In French Guiana, these strains are highly pathogenic in immunocompetent patients. They have defined a new clinical entity called Amazonian Toxoplasmosis. The present study aims to further improve our knowledge on the pathogenicity of these Amazonian *T. gondii* strains in comparison with three reference strains using Swiss strain mice. With these data, we tried to establish a predictive virulence score to classify these strains, but also to correlate this virulence with the severity of the disease in infected patients. **Results.** All the virulence indicators revealed that the Amazonian strains isolated in French Guiana presented a high virulence profile, but lower than the highly virulent type I reference RH strain. The findings reveal differences in virulence between human and animal strains, but also between anthropized and wild strains. **Conclusion.** In addition to being a clinically relevant animal model of Amazonian Toxoplasmosis, this model could also provide a solid experimental basis for future studies aiming to investigate the underlying mechanisms of Amazonian Toxoplasmosis disease.

Key words: Toxoplasmosis, Amazonian, French Guiana, Virulence, Mice.

Résumé – Virulence des souches atypiques de *Toxoplasma gondii* isolées en Guyane française chez un modèle murin. *Contexte.* *Toxoplasma gondii* est un parasite protozoaire intracellulaire obligatoire des vertébrés à sang chaud. La plupart des infections chez les patients immunocompétents sont asymptomatiques. Cependant, depuis les années 2000, des souches avec des profils génétiques particuliers qui diffèrent du type clonal connu (type I, II, III) ont été décrites. En Guyane française, ces souches sont hautement pathogènes chez les patients immunocompétents. Elles ont défini une nouvelle entité clinique appelée Toxoplasmose Amazonienne. La présente étude vise à approfondir nos connaissances sur le pouvoir pathogène de ces souches amazoniennes de *T. gondii* par rapport à 3 souches de référence en utilisant des souris de souche Swiss. Avec ces données, nous avons tenté d'établir un score de virulence prédictif pour classer ces souches mais également de corrélérer cette virulence avec la gravité de la maladie chez les patients infectés. **Résultats.** Tous les indicateurs de virulence ont révélé que les souches amazoniennes isolées en Guyane française présentaient une virulence élevée mais plus faible que la souche de référence RH très virulente de type I. Les résultats ont mis en évidence les différences de virulence entre les souches humaines et animales mais aussi entre les souches anthropisées et les souches sauvages. **Conclusion.** En plus d'être un modèle animal cliniquement pertinent de la toxoplasmose amazonienne, ce modèle pourrait également fournir une base expérimentale solide à de futurs travaux qui chercheront à approfondir les mécanismes sous-jacents de la toxoplasmose amazonienne.

*Corresponding author: stephane.simon@guyane.univ-ag.fr

Introduction

Discovered since 1908 [38, 51], *Toxoplasma gondii* is a parasite of warm-blooded vertebrates, including mammals, birds and humans [17]. This obligate intracellular protozoan is a cosmopolitan pathogen that is estimated to infect nearly one-third of the adult human population [24]. Humans are contaminated either by consumption of raw or undercooked meat containing tissue cysts or by accidental consumption of oocyst-contaminated vegetables or drinking contaminated water [23, 25, 29]. Until the last two decades, infection with *T. gondii* was usually considered to cause no illness, but only some mild clinical signs in immunocompetent individuals, specifically transient lymphadenopathy and mild flu-like presentations. Severe outcomes such as encephalitis, pneumonia, myocarditis, or disseminated infections were uncommon. It is well-known that infections acquired during pregnancy can result in mild to serious congenital defects in the fetus, and potentially evolve toward ocular infections [34, 40]. In immunocompromised individuals, such as transplant recipients and patients living with HIV, toxoplasmosis can result in severe consequences, including encephalitis, chorioretinitis, or myocarditis, which can potentially be fatal [4]. *Toxoplasma gondii* strains isolated in North America and Europe have been grouped into three major clonal lineages as types I, II, and III, based on six genetic markers [8, 26]. Several studies on experimental *T. gondii* infections have reported a correspondence between virulence in mice and genotype: type I strains such as RH are the most virulent with a 100% lethal dose (LD₁₀₀) of one parasite [47] less than 10 days after inoculation. In contrast, type II strains such as PRU have intermediate virulence (LD₅₀ > 10³), whereas type III strains such as VEG are almost avirulent (LD₅₀ > 10⁵) [49]. There may also be differences in the virulence of the three strains in humans [4, 8, 26]. The development of genetic analyses by RFLP-PCR [52] or microsatellites [5] showed more complex polymorphism for several strains isolated from Africa [6, 19, 22, 37], Asia [28, 32, 42] and South America [45, 53]. However, despite this complex polymorphism, some of these strains isolated from humans and animals can be grouped into haplogroups corresponding to clonal lineages across these continents [30, 31, 33, 36]. In French Guiana, an Amazonian tropical area, emerging strains exhibit high genetic diversity with strains belonging to different haplogroups (HG). It revealed that anthropized strains were closely grouped with HG3, while wild strains were grouped with HG5 or HG10 [31]. These strains can be responsible for a new clinical entity called Amazonian Toxoplasmosis. This is a severe form of systemic acquired toxoplasmosis among immunocompetent adults, with greater potential for death [2, 3, 9, 10, 13–16, 37, 46].

The present study aimed to improve our knowledge of the pathogenicity of these Amazonian *T. gondii* strains in comparison with the three reference strains using a murine model, and calculated mortality-linked parameters.

Materials and methods

Ethics statement

All experiments carried out in mice in this study were in agreement with the recommendations of European Directive

No. 86/609/EEC and French Decree No. 2013-118. The experimental protocols were approved by the Veterinary Services Department and by the Ethics Committee of the Institut Pasteur under the reference C2EA 89 – CETEA Institut Pasteur.

Experimental mice and parasites

Specific pathogen-free (SPF) Swiss CD1 mice were used (Charles River Laboratory, Lyon, France), and they were bred at the animal facility of Institut Pasteur de la Guyane.

In addition to the reference strains RH (type I), PRU (type II) and VEG (type III), 10 *T. gondii* strains isolated in French Guiana and genotyped by the microsatellite method (Table 1) were provided by the Biological Resource Center of Limoges (France). Five of them were isolated from patients and the other five strains were isolated from wild or domestic animals [3, 15, 37]. The tachyzoites were cultured and harvested by serial passages on monolayers of Human Foreskin Fibroblast cells (HFF-1, ATCC® number: SCRC-1041™) in Roswell Park Memorial Institute medium (RPMI) 1640 with L-glutamine (PAN Biotech GmbH, Aidenbach, Germany) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (PAN Biotech GmbH, Aidenbach, Germany), penicillin (100 U/mL) and streptomycin (100 µg/mL) (PAN Biotech GmbH, Aidenbach, Germany) at 37 °C in a humid 5% CO₂ atmosphere. HFF-1 monolayers were infected by 10⁵ tachyzoites and after 1 week, all cells were lysed. The tachyzoites were scraped and counted into a Kova cell chamber. The tachyzoites were diluted to the appropriate concentration in sterile isotonic saline (PBS). For each strain, different doses of tachyzoites ranging from 5, 5 × 10¹, 5 × 10², 5 × 10³ and 5 × 10⁴ were respectively inoculated intraperitoneally into groups of 10 mice (Group 1, Group 2, Group 3, Group 4, and Group 5). The parasite load of the inoculum was checked using *Toxoplasma* real-time PCR (Bio-Evolution, Bry-sur-Marne, France), according to the manufacturer's recommendations.

Dose effect and mouse virulence tests

The virulence of *T. gondii* strains was determined by monitoring clinical signs and cumulative mortality after peritoneal injection. We maintained 10 mice as uninfected controls (Group 0) by injecting sterile isotonic saline (PBS). The mice were clinically observed daily for 31 days. During the observation period, dead mice were counted. At the end of the observation period, live mice were counted and euthanized. *Toxoplasma* infection was controlled using *Toxoplasma* real-time PCR (Bio-Evolution) on the heart samples of the dead or euthanized mice.

Statistical analysis

Survival curve

Kaplan-Meier [41] plots were plotted, and the Log-rank test was used to compare survival of mice and the mortality data such as the mortality rate (MR) of the experimental groups. *p* values ≤ 0.05 were considered significant.

Table 1. Characteristics of the *Toxoplasma gondii* strains used in this study.

Isolate	BRC code	MS genotype	References	Origin	Host	Patient symptoms
RH	ND	Type I	[48]	North America	Human	
PRU	TgH00001	Type II	[30]	France	Human	
VEG	TgH00005	Type III	[48]	North America	Human	
GUY-WAY-2007	TgH18028	Amazonian	[37]	Maripasoula area*	Human	Fever, persistent bronchitis (severity: low) Hospitalization Favorable course with treatment
GUY-GRO-2011	TgH18049	Amazonian	N.C.	Maripasoula area*	Human	Fever, hepatitis (severity: intermediate) Hospitalization Favorable course with treatment
GUY-MEL-2003	TgH18007	Amazonian	[37]	Mana river*	Human	Fever, pneumopathy, heart damage (severity: intermediate) Hospitalization Death from heart damage, 2 years after treatment
GUY-AKO-2004	TgH18009	Amazonian	[37]	Apatou area*	Human	Fever, heart failure, anasarca (severity: high) Intensive care unit Favorable course with treatment
GUY-TOJ-2006	TgH18021	Amazonian	[37]	Apatou area*	Human	Fever, general failure (severity: very high) Intensive care unit Death despite treatment
GUY-CAN-FAM-0001	TgA18002	Caribbean1	[37]	Macouria*	Dog (<i>Canis familiaris</i>)	
GUY-CAN-FAM-0002	TgA18004	Caribbean2	[37]	Macouria*	Dog (<i>Canis familiaris</i>)	
GUY-CAN-FAM-0007	TgA18006	Amazonian	[37]	Roura*	Dog (<i>Canis familiaris</i>)	
GUY-JAG-2004	TgA18001	Amazonian	[37]	Belizon track*	Jaguar (<i>Panthera onca</i>)	
GUY-GAL-VIT-0001	TgA18005	Single isolate	[37]	Matoury*	Grison (<i>Galictis vittata</i>)	

Human Guyanese strains are classified by the severity of clinical signs observed. Animal strains are classified by the domestic or wild biotope. N.C.: Not communicated.

* Sites localized in French Guiana.

Dose effect curve

The dose effect analysis was based on a probit regression to model the impact of tachyzoite doses on the survival of a group of mice. The analysis made it possible to determine LD₅₀ and LD₉₉ which are respectively the required number of parasites to kill 50% or 99% of infected mice. Statistical analyses and graphics were performed using XLSTAT-Biomed [1].

Predictive score of virulence

Virulence is generally defined as the intensity of an infectious microorganism's pathogenicity for its host. To better define and objectively quantify *T. gondii* virulence in mice, we determined a predictive virulence score for each strain. For this, we used several parameters such as injected dose,

infected population, median number of days of survival after infection, and mortality rate, and defined the virulence score as:

Virulence score (VS)

$$= \text{Average} \left(\sum \left(\left(\frac{1}{\log(n_{\text{tachy}})} \times \frac{1}{\text{median survival}} \right) \times \left(\frac{n_{\text{death}} \times 100}{n_{\text{injected}}} \right) \right) \right)$$

n_{tachy} : number of injected tachyzoites,

median survival : median of survival days per the number of injected tachyzoites,

n_{death} : number of mice that died per the injected dose,

n_{injected} : number of injected mice.

This score was used to objectively compare the different *T. gondii* strains with each other, especially strains of unknown virulence versus reference strains.

Results

The appearance of the disease in mice is characterized by clinical signs (respiratory distress, ruffled hair, asthenia, sluggishness). Death occurs, in general, between 3 and 5 days after the appearance of the first signs. Autopsy of the mice showed significant damage to the heart, lungs and brain (data not shown). These pathophysiological features are similar to those seen in the most severely infected patients.

The presence of *Toxoplasma gondii* was verified by qPCR on heart samples of all the mice (either dead during the experiment, or euthanized after the 31 days of testing). All samples were positive confirming the presence of *T. gondii* in all mice.

Survival curves in infected mice

The differences of mice survival depending on the infecting dose injected are shown in [Figure 1](#). Unsurprisingly, we confirmed that the greater the injected dose, the higher the number of deaths observed.

When 5 tachyzoites were injected, the RH and GUY-GRO-2011 strains killed the entire group of mice in 12 days and 22 days, respectively. For the other Guianese strains, the MR was less than or equal to 70% after 31 days except the GUY-GAL-VIT0001 strain whose MR is 90% at 15 days. It was 20% and 0% after 31 days for the PRU (type II) and VEG (type III) strains, respectively.

When 50 tachyzoites were injected, the GUY-CAN-FAM0007 and GUY-GAL-VIT0001 strains killed the entire group of mice in 18 days and 15 days, respectively. For 5 strains such as GUY-AKO-2004, GUY-TOJ-2006, GUY-WAY-2007, GUY-CAN-FAM0002 and GUY-JAG-2004, the MR was 90%. It was 40% and 10% for PRU and VEG strains, respectively.

When 500 tachyzoites were injected, all the Guianese strains had a 100% MR between 13 and 19 days, whereas the PRU and VEG strains had mortality rates of 40% and 30%, respectively.

The higher the injected dose of tachyzoites, the shorter the time to death ([Table 2](#)). The median survival time of mice injected with 5 tachyzoites (minimum doses) for the RH strain was 10.4 days (with an MR of 100%), 19.5 days for PRU (with an MR of 20%), and there was no mortality for VEG. The median survival time with 5×10^4 tachyzoites (maximum dose) for the RH strain was 7.6 days (with an MR of 100%), 14.5 days for PRU (with an MR of 50%), and 19 days for VEG (with an MR of 40%). For Guianese strains, the median survival time ranged between 12.1 (GUY-GAL-VIT0001) and 19.5 (GUY-GRO-2011) days for a dose of 5 tachyzoites and between 8.6 (GUY-GAL-VIT0001) and 13.8 (GUY-CAN-FAM0002) days for an inoculum of 5×10^4 tachyzoites injected ([Table 2](#)).

Determination of LD₅₀ and LD₉₉

The mortality rate (MR) of the mice after 31 days post infection according to the strain is shown in [Figure 2](#). The profile of the three reference strains is very specific. The RH strain showed a highly virulent profile with 100% mortality for a very small amount of injected tachyzoites. The PRU strain had a less

aggressive profile with an MR between 20% and 50%, and the VEG strain was almost as virulent because the mortality rate varied from 0% to 40% for a number of injected tachyzoites ranging from 5 to 5×10^4 . We highlighted that, when compared with the reference strains, the Guianese strains had profiles close to the RH strains.

We used the line equation to calculate LD₅₀ and LD₉₉ which are respectively the required amount of parasites to kill 50% or 99% of infected mice ([Table 3](#)). The reference strains RH, PRU and VEG had an LD₅₀ of 1, 3933 and 126,373 tachyzoites, respectively and an LD₉₉ of 4, 2×10^{13} and 1.5×10^{10} tachyzoites, respectively. French Guianese strains had an LD₅₀ value ranging between 1 and 10 tachyzoites, and an LD₉₉ value between 7 and 1018 tachyzoites. These values confirm the virulent profile of the Guianese strains.

Virulence score in mice

We first determined the levels of virulence in murine models for the reference strains ([Fig. 3](#)). The highly virulent RH strain corresponded to a high score of 5.89. The intermediate virulent PRU strain had a score of 1.07, and the non-virulent strain had a low score of 0.32.

We then compared the virulence scores with the severity of the symptoms caused in infected patients. Patients were classified with increasing severity ([Table 1](#)), thus virulence scores should also increase. There was an increase in the score for the first four patients (GUY-WAY-2007, GUY-GRO-2011, GUY-MEL-2003 and GUY-AKO-2004) who had a virulence score of 3.01, 3.40, 3.48 and 3.55, respectively. However, the last patient had the most severe symptoms (death), but his score was only 3.28. We hypothesized that scores would increase with increasing symptom severity in patients. This was confirmed in the first four patients, but this increase was very low compared to the symptoms in the different patients. The difference in score between a patient with persistent bronchitis and a patient in an intensive care unit was only 0.54.

The scores determined for the strains isolated from animals were more heterogeneous ranging from 2.42 for the GUY-JAG-2004 strain to 4.9 for the GUY-GAL-VIT0001 strain.

The Guianese strains ranged between the highly virulent RH strain and the intermediate virulent PRU strain. This seems to indicate rather high virulence especially for the GUY-GAL-VIT0001 strain, which showed a very high score. However, although its mortality rate was not the highest, its score was high because the death of the mice occurred very quickly after the injection.

Discussion

To our knowledge, the present experimental results on *Toxoplasma* virulence in mice are original. Most articles explore the virulence in mice from very specific approaches. Some experiments are much more focused on analyzing the correlation between clinical data and biological markers of acute, chronic or secondary infections involving European or North-American strains [27], while others attempt to demonstrate the basic patterns of *T. gondii* pathophysiological




Figure 1. Virulence in mice of atypical *Toxoplasma gondii* strains isolated in French Guiana compared to reference strains (type I, II and III). Ten mice/groups were inoculated intraperitoneally with different doses of tachyzoites for each strain, and the viability of mice was monitored daily. Survival was followed up for 31 days after injection and data were plotted as Kaplan-Meier curves (statistical significance of survival curves between RH and others strains, $p \leq 0.001$).

Table 2. Median survival days ($\pm SD$) of mice inoculated with different doses of parasites.

	<i>T. gondii</i> strains													
	RH	PRU	VEG	GUY-AKO-2004	GUY-GRO-2011	GUY-MEL-2003	GUY-TOJ-2006	GUY-WAY-2007	GUY-CAN-FAM0001	GUY-CAN-FAM0002	GUY-CAN-FAM0007	GUY-JAG-2004	GUY-GAL-VIT0001	
Doses of parasites	5×10^0	10.4 ± 0.5	19.5 ± 1.0	Undefined	13.3 ± 2.0	19.5 ± 1.9	14.2 ± 1.2	15.7 ± 1.8	15.4 ± 1.5	13.3 ± 0.9	15.8 ± 1.7	15.3 ± 1.2	15.7 ± 1.5	12.1 ± 1.2
	5×10^1	10.0 ± 0.3	18.3 ± 2.2	23	13.2 ± 1.2	16.5 ± 1.0	13.8 ± 1.0	14.4 ± 1.1	13.6 ± 0.5	14.0 ± 1.2	15.6 ± 1.3	14.9 ± 1.3	16.2 ± 1.3	12.0 ± 1.0
	5×10^2	9.4 ± 0.7	16.8 ± 3.0	21	12.8 ± 1.7	15.3 ± 0.7	12.0 ± 0.7	14.3 ± 1.1	12.2 ± 1.0	13.4 ± 0.9	14.7 ± 1.5	12.4 ± 1.2	15.4 ± 1.0	10.4 ± 1.0
	5×10^3	8.8 ± 0.7	16.2 ± 3.9	20.3 ± 3.5	11.5 ± 1.0	14.0 ± 0.7	11.1 ± 0.9	13.9 ± 1.3	10.9 ± 0.5	12.6 ± 1.8	14.8 ± 1.6	11.5 ± 0.9	14.4 ± 1.3	9.2 ± 0.8
	5×10^4	7.6 ± 0.7	14.5 ± 2.8	19.0 ± 3.8	10.3 ± 1.4	12.1 ± 0.5	8.9 ± 0.9	11.7 ± 1.7	9.4 ± 0.5	11.9 ± 0.9	13.8 ± 1.5	9.6 ± 0.7	11.8 ± 0.8	8.6 ± 0.7



**Figure 2.** Determination of LD₅₀ and LD₉₉ for the 10 atypical strains of *Toxoplasma gondii* compared to reference strains (type I, II and III). Dose effect curves using a Probit model (black). Confidence interval (95%) curves are also shown (grey). On top of the figure, the tree reference strains (I, II and III) are shown for comparison.

Table 3. Determination of LD₅₀ and LD₉₉.

	<i>T. gondii</i> strains												
	RH	PRU	VEG	GUY-AKO-2004	GUY-GRO-2011	GUY-MEL-2003	GUY-TOJ-2006	GUY-WAY-2007	GUY-CAN-FAM 0001	GUY-CAN-FAM 0002	GUY-CAN-FAM0007	GUY-JAG-2004	GUY-GAL-VIT0001
DL ₅₀	1	3933	126,273	3	1	3	2	5	8	7	4	10	2
DL ₉₉	4	2E + 13	1.5E + 10	327	7	1018	745	465	561	217	12	182	9

**Figure 3.** Scoring of virulence of *Toxoplasma gondii* strains isolated in French Guiana compared to reference strains type I, II and III. The first three strains are the reference strains, the next five strains are isolated from patients (with an increase in the severity of the symptoms), and the last five strains are isolated from animals (three from domestic fauna and two from wildlife).

mechanisms using transgenic mice [11, 19, 44] or other advanced technologies, such as bioluminescence imaging [7]. Some general reviews reported data from experimental assays and overviewed hypotheses underlying toxoplasma virulence based on general comparisons between different genotypic strains including the clonal reference ones [18, 21, 35, 50]. Recently, Saraf et al. [43], proposed a standardized methodology for future studies in order to enable more efficient and effective analysis of genetics and virulence patterns for *T. gondii*.

Our study, despite being performed before the publication of this article, complied with its instructions except for: (i) the determination of seroconversion by modified agglutination test (MAT) as we used *T. gondii* qPCR to confirm the infection, (ii) the number of mice injected per group, 10 instead of 5, in order to improve the performance and robustness of the study, and (iii) the studied parameters, such as the determination of the DL₁₀₀ and DL₉₉, and calculated the cumulative mortality rate using another approach. In fact, we concentrated on determining a virulence score by considering several relevant parameters such as the survival time, the amount of injected tachyzoites, and the cumulative MR.

This parameter seemed to be an objective and useful tool to evaluate virulence in mice. It matched with the other results of

this study and was validated by the good correspondence of its values with clinical classes (virulent, intermediate and non-virulent) for the reference strains. It could thus be used to compare the strains among one another, especially strains isolated from diverse geographical areas, and enabled us to correlate the virulence of these strains with the clinical features in humans, when there are human contaminations. We emphasize that this experiment obviously cannot be extrapolated to other experimental rodent species: susceptibility to *T. gondii* infection varies among different hosts [12, 17] and laboratory mice, generally sensitive, are often used as the preferred animal model to determine parasite virulence.

The RH strain (type I) had a 100% mortality rate with five injected tachyzoites. The PRU (type II) and VEG (type III) strains did not have a 100% mortality rate. However, all these Guianese strains had a 100% mortality rate with only 500 tachyzoites injected. This suggests that the atypical *T. gondii* strains circulating in French Guiana have virulence factors comparable to those established by the type I strain compared to those of type II or type III. This fitted with the results of the virulence score. Regarding this parameter, we should highlight the differences between strains isolated from humans and animals, and even within the strains isolated from animals. It is

unclear whether this should be explained by the geographic origin of the strains or by the type of intermediate or definitive hosts clearly, recent studies revealed that in French Guiana, there are two *T. gondii* environmental populations, the wild population with very high genetic diversity, and the anthropized population presenting lower genetic diversity [37].

Thus, in this study, the strains isolated from humans (Amazonian type) showed elevated high virulence scores with a median of 3.34, but lower than that of the RH strain (5.89). According to patient surveys and their reported risk factors [9, 16], these strains were related to wild environments. Except for two patients who developed mild pneumopathy (GUY-WAY-2007, GUY-MEL-2003), the others presented severe infections with organ failure (heart, kidneys, liver, lungs). Patients were classified by the degree of severity of symptoms (Table 1). However, the classification of patients by severity was difficult because other factors than the infecting strain can influence the intensity of human disease (host genetic factors, inocula, etc.). The low variation of the virulence score between the patient with pneumopathy (GUY-WAY-2007) and the patient with cardiac involvement (GUY-AKO-2004) did not reveal an obvious correlation between the degree of severity and the virulence score. In addition, the last patient had the most serious symptoms but his score was one of the lowest because this patient was already weakened during the contamination, unlike the other four.

However, these scores are higher than for the PRU (type II) strain, indicating fairly strong pathogenicity of these Amazonian strains.

Concerning the animal strains, our findings reported a heterogeneous virulence score. The lowest value was 2.42 and concerned a strain isolated from a free-living *Panthera onca*, GUY-JAG-2004 [15], while the highest value was 4.90 for the GUY-GAL-VIT0001 strain isolated from a wild animal (greater grison: *Galictis vittata*, Mustelidae) close to an anthropized environment located on the thin coastal border (disturbed forest near the city of Cayenne) [37]. A very high virulence score comparable to that of human strains was calculated for one strain isolated from a dog in the anthropized area (GUY-CAN-FAM0007), whereas those from the other two dogs presented intermediate virulence scores. These two strains which genetically belong to the “Caribbean” 1 and 2 types (respectively GUY-CAN-FAM0001 and GUY-CAN-FAM0002) have been isolated essentially from animals circulating in anthropized areas, and are genotypes that are found throughout the Caribbean and part of South America. They are therefore potentially strains imported by human activity into French Guiana [37]. Little is known about the severity of the symptoms caused by these strains in a contaminated patient. Although an isolated case has demonstrated the opposite, we could expect that they are presumably more symptomatic than those caused by European strains, but still lack the specific severity of Amazonian Toxoplasmosis according to several recorded cases [16, 36].

The lower score of strain GUY-JAG-2004 was interesting because this strain was typed “Amazonian” by Mercier et al. [37]. This strain appeared to have a common ancestor with the type II strain. In a recent classification [33], Guianese strains belong to haplogroups 5 and 10, grouped in clade F and

GUY-JAG-2004 is similar with microsatellite typing to a strain isolated from cougars in Canada, belonging to HG11. These strains belong to the ancestral clade D in which there are type II strains. This may explain its lower virulence for mice.

Contrary to our expectations (we had predicted a very high virulence score for the wild strains and a low virulence score for the anthropized strains [36]); there was no obvious correlation between ecological origin and virulence score. Such assays seem interesting to classify strains, rank them by severity, and have a better overview of their potential clinical severity, especially in the case of strains for which little or no clinical information in humans has yet been identified (e.g., Caribbean strains).

Although the number of studied strains was low, the first results revealed that the Guianese strains had a higher virulence than type II strains usually found in Europe and North America. However, virulence is weaker than the highly virulent type I strain. In addition, the study of a larger number of Amazonian strains and reference strains would make it possible to verify our model. Furthermore, the study of strains with a greater number of mice could have an influence on the precision of the virulence score. However, these experiments require the use of a large number of mice, which raises ethical questions.

At present, there is not much information on the virulence mechanisms of these Guianese strains. A study showed the variation of polymorphic rho-try protein kinases ROP18 and ROP5 of Guianese strains with other strains [39]. Our model would make it possible to develop reliable experimental tests to better describe the genetic or immunological virulence factors of these Amazon strains.

In conclusion, the virulence indicators revealed that the Amazonian strains presented a high virulence profile, but weaker than the highly virulent type I reference. There were differences in virulence between human and animal strains, but also between anthropized and wild strains. In addition to being a clinically relevant animal model of Amazonian Toxoplasmosis, this model could also provide a solid experimental basis for future studies aiming to investigate the underlying pathophysiology of Amazonian Toxoplasmosis.

Conflict of interest

The authors declare that there is no conflict of interest.

Acknowledgements. This work benefited from an “Investissement d’Avenir” grant managed by the French National Research Agency (ANR) (CEBA, ref. ANR-10-LABX-25-01) and from a European Regional Development Fund (ERDF) grant (FEDER présage n° 30820).

References

1. Addinsoft. 2017. XLSTAT 2017: Logiciel de statistiques et d’analyse de données pour Microsoft Excel. Paris, France: Addinsoft.
2. Ajzenberg D, Cogne N, Paris L, Bessieres MH, Thulliez P, Filisetti D, Pelloux H, Marty P, Dardé ML. 2002. Genotype of 86 *Toxoplasma gondii* isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. *Journal of Infectious Diseases*, 186(5), 684–689.

3. Ajzenberg D, Bañuls AL, Su C, Dumetre A, Demar M, Carne B, Dardé ML. 2004. Genetic diversity, clonality and sexuality in *Toxoplasma gondii*. *International Journal for Parasitology*, 34(10), 1185–1196.
4. Ajzenberg D, Yera H, Marty P, Paris L, Dalle F, Menotti J, Aubert D, Franck J, Bessieres MH, Quinio D, Pelloux H, Delhaes L, Desbois N, Thulliez P, Robert-Gagneux F, Kauffmann-Lacroix C, Pujol S, Rabodonirina M, Bougnoux ME, Cuisenier B, Duhamel C, Duong TH, Filisetti D, Flori P, Gay-Andrieu F, Pratlong F, Nevez G, Totet A, Carne B, Bonnabau H, Dardé ML, Villena I. 2009. Genotype of 88 *Toxoplasma gondii* isolates associated with toxoplasmosis in immunocompromised patients and correlation with clinical findings. *Journal of Infectious Diseases*, 199(8), 1155–1167.
5. Ajzenberg D, Collinet F, Mercier A, Vignoles P, Dardé ML. 2010. Genotyping of *Toxoplasma gondii* isolates with 15 microsatellite markers in a single multiplex PCR assay. *Journal of Clinical Microbiology*, 48(12), 4641–4645.
6. Al-Kappany YM, Rajendran C, Abu-Elwafa SA, Hilali M, Su C, Dubey JP. 2010. Genetic diversity of *Toxoplasma gondii* isolates in Egyptian feral cats reveals new genotypes. *Journal of Parasitology*, 96(6), 1112–1114.
7. Avci P, Karimi M, Sadasivam M, Antunes-Melo WC, Carrasco E, Hamblin MR. 2018. In-vivo monitoring of infectious diseases in living animals using bioluminescence imaging. *Virulence*, 9(1), 28–63.
8. Behnke MS, Khan A, Wootton JC, Dubey JP, Tang K, Sibley LD. 2011. Virulence differences in *Toxoplasma* mediated by amplification of a family of polymorphic pseudokinases. *Proceedings of the National Academy of Sciences of the United States of America*, 108, 9631–9636.
9. Carne B, Bissuel F, Ajzenberg D, Bouyne R, Aznar C, Demar M, Bichat S, Louvel D, Bourbigot AM, Peneau C, Neron P, Dardé ML. 2002. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. *Journal of Clinical Microbiology*, 40(11), 4037–4044.
10. Carne B, Demar M, Ajzenberg D, Dardé ML. 2009. Severe acquired toxoplasmosis caused by wild cycle of *Toxoplasma gondii*, French Guiana. *Emerging Infectious Diseases*, 15(4), 656–658.
11. Cruz A, Mendes EA, de Andrade MV, do Nascimento VC, Cartelle CT, Arantes RM, Melo JR, Gazzinelli RT, Ropert C. 2014. Mast cells are crucial in the resistance against *Toxoplasma gondii* oral infection. *European Journal of Immunology*, 44(10), 2949–2954.
12. Cunningham AA, Buxton D, Thomson KM. 1992. An epidemic of toxoplasmosis in a captive colony of squirrel monkeys (*Saimiri sciureus*). *Journal of Comparative Pathology*, 107(2), 207–219.
13. Dardé ML, Bouteille B, Pestre-Alexandre M. 1992. Isoenzyme analysis of 35 *Toxoplasma gondii* isolates and the biological and epidemiological implications. *Journal of Parasitology*, 78(5), 786–794.
14. Demar M, Ajzenberg D, Maubon D, Djossou F, Panchoe D, Punwasi W, Valery N, Peneau C, Daigre JL, Aznar C, Cottrelle B, Terzan L, Dardé ML, Carne B. 2007. Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. *Clinical Infectious Diseases*, 45(7), 88–95.
15. Demar M, Ajzenberg D, Serrurier B, Dardé ML, Carne B. 2008. Atypical *Toxoplasma gondii* strain from a free-living jaguar (*Panthera onca*) in French Guiana. *American Journal of Tropical Medicine and Hygiene*, 78(2), 195–197.
16. Demar M, Hommel D, Djossou F, Peneau C, Boukhari R, Louvel D, Bourbigot AM, Nasser V, Ajzenberg D, Dardé ML, Carne B. 2012. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. *Clinical Microbiology and Infection*, 18(7), 221–231.
17. Dubey JP. 2010. *Toxoplasmosis of Animals and Humans*, 2nd edn. Florida: Boca Raton. Book, Whole
18. Dubey JP, Rajendran C, Ferreira LR, Kwok OC, Sinnott D, Majumdar D, Su C. 2010. A new atypical highly mouse virulent *Toxoplasma gondii* genotype isolated from a wild black bear in Alaska. *Journal of Parasitology*, 96(4), 713–716.
19. Dubey JP, Ferreira LR, Martins J, McLeod R. 2012. Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with *Toxoplasma gondii* strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. *Parasitology*, 139(1), 1–13.
20. Dubey JP, Choudhary S, Tilahun G, Tiao N, Gebreyes WA, Zou X, Su C. 2013. Genetic diversity of *Toxoplasma gondii* isolates from Ethiopian feral cats. *Veterinary Parasitology*, 196(1–2), 206–208.
21. Dubey JP, Alvarado-Esquivel C, Herrera-Valenzuela VH, Ortiz-Diaz JJ, Oliveira S, Verma SK, Choudhary S, Kwok OC, Su C. 2013. A new atypical genotype mouse virulent strain of *Toxoplasma gondii* isolated from the heart of a wild caught puma (*Felis concolor*) from Durango, Mexico. *Veterinary Parasitology*, 197(3–4), 674–677.
22. Galal L, Ajzenberg D, Hamidovic A, Durieux MF, Darde ML, Mercier A. 2018. *Toxoplasma* and Africa: one parasite, two opposite population structures. *Trends in Parasitology*, 34(2), 140–154.
23. Gotteland C, Gilot-Fromont E, Aubert D, Poulle ML, Dupuis E, Darde ML, Forin-Wiart MA, Rabilloud M, Riche B, Villena I. 2014. Spatial distribution of *Toxoplasma gondii* oocysts in soil in a rural area: influence of cats and land use. *Veterinary Parasitology*, 205(3–4), 629–637.
24. Grigg ME, Sundar N. 2009. Sexual recombination punctuated by outbreaks and clonal expansions predicts *Toxoplasma gondii* population genetics. *International Journal for Parasitology*, 39(8), 925–933.
25. Guo M, Dubey JP, Hill D, Buchanan RL, Gamble HR, Jones JL, Pradhan AK. 2015. Prevalence and risk factors for *Toxoplasma gondii* infection in meat animals and meat products destined for human consumption. *Journal of Food Protection*, 78(2), 457–476.
26. Howe DK, Sibley LD. 1995. *Toxoplasma gondii* comprises three clonal lineages: correlation of parasite genotype with human disease. *Journal of Infectious Diseases*, 172(6), 1561–1566.
27. Jensen KD, Camejo A, Melo MB, Cordeiro C, Julien L, Grotenbreg GM, Frickel EM, Ploegh HL, Young L, Saeij JP. 2015. *Toxoplasma gondii* superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination. *mBio*, 6(2), e02280–e02314.
28. Jiang HH, Huang SY, Zhou DH, Zhang XX, Su C, Deng SZ, Zhu XQ. 2013. Genetic characterization of *Toxoplasma gondii* from pigs from different localities in China by PCR-RFLP. *Parasites & Vectors*, 6, 227–231.
29. Karanis P, Aldeyarbi HM, Mirhashemi ME, Khalil KM. 2013. The impact of the waterborne transmission of *Toxoplasma gondii* and analysis efforts for water detection: an overview and update. *Environmental Science and Pollution Research International*, 20(1), 86–99.
30. Khan A, Fux B, Su C, Dubey JP, Dardé ML, Ajioka JW, Rosenthal BM, Sibley LD. 2007. Recent transcontinental sweep of *Toxoplasma gondii* driven by a single monomorphic chromosome. *Proceedings of the National Academy of Sciences of the United States of America*, 104, 14872–14877.
31. Khan A, Ajzenberg D, Mercier A, Demar M, Simon S, Darde ML, Wang Q, Verma SK, Rosenthal BM, Dubey JP, Sibley LD. 2014. Geographic separation of domestic and wild strains of *Toxoplasma gondii* in French Guiana correlates with a

- monomorphic version of chromosome 1a. *PLoS Neglected Tropical Diseases*, 8(9), e3182.
32. Li M, Mo XW, Wang L, Chen H, Luo QL, Wen HQ, Wei W, Zhang AM, Du J, Lu FL, Lun ZR, Shen JL. 2014. Phylogeny and virulence divergency analyses of *Toxoplasma gondii* isolates from China. *Parasites & Vectors*, 7, 133.
 33. Lorenzi H, Khan A, Behnke MS, Namasivayam S, Swapna LS, Hadjithomas M, Karamycheva S, Pinney D, Brunk BP, Ajioka JW, Ajzenberg D, Boothroyd JC, BoyleJP Dardé ML, Diaz-Miranda MA, Dubey JP, Fritz HM, Gennari SM, Gregory BD, Kim K, Saeij JP, Su C, White MW, Zhu XQ, Howe DK, Rosenthal BM, Grigg ME, Parkinson J, Liu L, Kissinger JC, Roos DS, Sibley LD. 2016. Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic *Toxoplasma gondii* genomes. *Nature Communications*, 7, 10147.
 34. McAuley JB. 2014. Congenital Toxoplasmosis. *Journal of the Pediatric Infectious Diseases Society*, 3(Suppl 1), S30–S35.
 35. Melo RPB, Almeida JC, Lima DCV, Pedrosa CM, Magalhaes FJR, Alcantara AM, Barros LD, Vieira RFC, Garcia JL, Mota RA. 2016. Atypical *Toxoplasma gondii* genotype in feral cats from the Fernando de Noronha Island, northeastern Brazil. *Veterinary Parasitology*, 224, 92–95.
 36. Mercier A, Devillard S, Ngoubangoye B, Bonnabau H, Banuls AL, Durand P, Salle B, Ajzenberg D, Dardé ML. 2010. Additional haplogroups of *Toxoplasma gondii* out of Africa: population structure and mouse-virulence of strains from Gabon. *PLoS Neglected Tropical Diseases*, 4(11), e876.
 37. Mercier A, Ajzenberg D, Devillard S, Demar MP, de Thoisy B, Bonnabau H, Collinet F, Boukhari R, Blanchet D, Simon S, Carme B, Dardé ML. 2011. Human impact on genetic diversity of *Toxoplasma gondii*: example of the anthropized environment from French Guiana. *Infection, Genetics and Evolution*, 11(6), 1378–1387.
 38. Nicolle C, Manceaux L. 1909. Sur un protozoaire nouveau du gondi. *Comptes Rendus Hebdomadaires des Séances de l'Académie des Sciences*, 148, 368–372.
 39. Nieldman W, Gold DA, Rosowski EE, Sprockholt JK, Lim D, Farid Arenas A, Melo MB, Spooner E, Yaffe MB, Saeij JP. 2012. The roptry proteins ROP18 and ROP5 mediate *Toxoplasma gondii* evasion of the murine, but not the human, interferon-gamma response. *PLoS Pathogens*, 8(6), e1002784.
 40. Pleyer U, Schluter D, Manz M. 2014. Ocular toxoplasmosis: recent aspects of pathophysiology and clinical implications. *Ophthalmic Research*, 52(3), 116–123.
 41. Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. 2010. A practical guide to understanding Kaplan-Meier curves. *Otolaryngology-Head and Neck Surgery*, 143(3), 331–336.
 42. Salant H, Hamburger J, King R, Baneth G. 2013. *Toxoplasma gondii* prevalence in Israeli crows and Griffon vultures. *Veterinary Parasitology*, 191(1–2), 23–28.
 43. Saraf P, Shwab EK, Dubey JP, Su C. 2017. On the determination of *Toxoplasma gondii* virulence in mice. *Experimental Parasitology*, 174, 25–30.
 44. Seng S, Yokoyama M, Suzuki R, Maki Y, Kato M, Lim C, Zayatiin B, Inoue N, Xuan X, Igarashi I, Nagasawa H, Fujisaki K, Mikami T, Suzuki N, Toyoda Y. 2000. Expression of SAG-1 of *Toxoplasma gondii* in transgenic mice. *Parasitology Research*, 86(4), 263–269.
 45. Shwab EK, Zhu XQ, Majumdar D, Pena HF, Gennari SM, Dubey JP, Su C. 2014. Geographical patterns of *Toxoplasma gondii* genetic diversity revealed by multilocus PCR-RFLP genotyping. *Parasitology*, 141(4), 453–461.
 46. Shwab EK, Saraf P, Zhu XQ, Zhou DH, McFerrin BM, Ajzenberg D, Schares G, Hammond-Aryee K, van Helden P, Higgins SA, Gerhold RW, Rosenthal BM, Zhao X, Dubey JP, Su C. 2018. Human impact on the diversity and virulence of the ubiquitous zoonotic parasite *Toxoplasma gondii*. *Proceedings of the National Academy of Sciences of the United States of America*, 115(29), E6956–E6963.
 47. Sibley LD, Boothroyd JC. 1992. Virulent strains of *Toxoplasma gondii* comprise a single clonal lineage. *Nature*, 359(6390), 82–85.
 48. Sibley LD, Mordue DG, Su C, Robben PM, Howe DK. 2002. Genetic approaches to studying virulence and pathogenesis in *Toxoplasma gondii*. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences Royal Society (Great Britain)*, 357(1417), 81–88.
 49. Sibley LD, Ajioka JW. 2008. Population structure of *Toxoplasma gondii*: clonal expansion driven by infrequent recombination and selective sweeps. *Annual Review of Microbiology*, 62, 329–351.
 50. da Silva JR, Maciel BM, de Santana Souza Santos LKN, Carvalho FS, de Santana Rocha D, Lopes CWG, Albuquerque GR. 2017. Isolation and genotyping of *Toxoplasma gondii* in Brazilian dogs. *Korean Journal of Parasitology*, 55(3), 239–246.
 51. Splendore A. 1908. Un nuovo protozoa parassita deconigli incontrato nelle lesioni anatomiche d'una malattia che ricorda in molti punti il Kalaazar dell'uomo. Nota preliminare pel. *Revista da Sociedade Scientífica de São Paulo*, 3, 109–112.
 52. Su C, Zhang X, Dubey JP. 2006. Genotyping of *Toxoplasma gondii* by multilocus PCR-RFLP markers: a high resolution and simple method for identification of parasites. *International Journal for Parasitology*, 36(7), 841–848.
 53. Vitaliano SN, Soares HS, Minervino AH, Santos AL, Werther K, Marvulo MF, Siqueira DB, Pena HF, Soares RM, Su C, Gennari SM. 2014. Genetic characterization of *Toxoplasma gondii* from Brazilian wildlife revealed abundant new genotypes. *International Journal for Parasitology: Parasites and Wildlife*, 3(3), 276–283.

Cite this article as: Simon S, de Thoisy B, Mercier A, Nacher M & Demar M. 2019. Virulence of atypical *Toxoplasma gondii* strains isolated in French Guiana in a murine model. *Parasite* 26, 60.



An international open-access, peer-reviewed, online journal publishing high quality papers on all aspects of human and animal parasitology

Reviews, articles and short notes may be submitted. Fields include, but are not limited to: general, medical and veterinary parasitology; morphology, including ultrastructure; parasite systematics, including entomology, acarology, helminthology and protistology, and molecular analyses; molecular biology and biochemistry; immunology of parasitic diseases; host-parasite relationships; ecology and life history of parasites; epidemiology; therapeutics; new diagnostic tools.

All papers in Parasite are published in English. Manuscripts should have a broad interest and must not have been published or submitted elsewhere. No limit is imposed on the length of manuscripts.

Parasite (open-access) continues **Parasite** (print and online editions, 1994-2012) and **Annales de Parasitologie Humaine et Comparée** (1923-1993) and is the official journal of the Société Française de Parasitologie.

Editor-in-Chief:
Jean-Lou Justine, Paris

Submit your manuscript at
<http://parasite.edmgr.com/>